SRR1464411
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1323807 | GTEX | — | 0.962 |
| 2 | SRR1079168 | GTEX | — | 0.933 |
| 3 | SRR1441701 | GTEX | — | 0.917 |
| 4 | SRR1315994 | GTEX | — | 0.917 |
| 5 | SRR1387989 | GTEX | — | 0.915 |
| 6 | SRR1468403 | GTEX | — | 0.914 |
| 7 | SRR819534 | GTEX | — | 0.911 |
| 8 | SRR660103 | GTEX | — | 0.908 |
| 9 | SRR1073755 | GTEX | — | 0.903 |
| 10 | SRR1470035 | GTEX | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.469 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.408 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.399 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.355 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.307 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.294 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.262 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.259 | Inavolisib | — uncovered |
| COMPLEMENT | 0.257 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.245 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.239 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.197 | Inavolisib | — uncovered |
| COAGULATION | 0.192 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.162 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.145 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.132 | Inavolisib | — uncovered |
| HYPOXIA | 0.131 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.119 | Inavolisib | — uncovered |